Clinical Trials Logo

Clinical Trial Summary

This study is a prospective single-arm phase II clinical study. Advanced gastric and colorectal tumor patients with FGFR 1-3 alterations who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05202236
Study type Interventional
Source Wuhan Union Hospital, China
Contact Tao Zhang, Doctor
Phone 8618971656660
Status Recruiting
Phase Phase 2
Start date October 13, 2021
Completion date October 13, 2024